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Summary 
Interleukin 10 (IL-10) has recently been shown to induce normal human B lymphocytes to proliferate 
and differentiate into immunoglobulin  (Ig)-secreting cells. Herein, we show that IL-10 also promotes 
DNA synthesis and IgM production by anti-CD40 activated B cell chronic lymphocytic  leukemia 
(B-CLL). Most strikingly, IL-2 and IL-10 were found to synergize to induce the proliferation 
and differentiation of B-CLL cells. This synergy between IL-2 and IL-10 was also observed with 
normal B cells which proliferated strongly and secreted large amounts of IgM, IgG, and IgA. 
The observed synergy is likely to be due to the IL-10-induced increase of high affinity  IL-2 
receptors on both normal and leukemic B cells. This increase of high affinity receptor is associated 
to an increase of Tac/CD25 expression that can be detected by flow cytometric analysis. Taken 
together, these results indicate that IL-10 permits anti-CD40 activated B cells to respond to IL-2 
through an induction of high affinity  IL-2 receptors.  This effect of IL-IO may partly explain 
how T  cells, which activate B cells in a CD40-dependent fashion, induce B cell proliferation 
and differentiation mostly through IL-2. 
T 
he maturation of B cells into efficient producers of high 
affinity  and high specificity antibodies is regulated by 
various cell types through cell surface molecules and soluble 
cytokines. In vitro studies have demonstrated the important 
role of IL-2, IL-4, and IL-10 on B cell maturation (1). IL-10 
originally isolated for its ability to inhibit the production of 
IFN-  7 (2), acts as a growth and, most notably, a differentia- 
tion factor for normal B lymphocytes activated through their 
CD40 antigen or their antigen receptor (3, 4). IL-2 was found 
to be a potent proliferation- and differentiation-inducing agent 
of B lymphocytes after crosslinking of their surface Igs (5, 
6). However, the effects of IL-2 on the growth and differen- 
tiation of anti-CD40 activated B cells were constantly minor 
(7). The reactivity of B lymphocytes to IL-2 is mediated by 
high affinity  receptors (Kd  =  10-11M),  which display  at 
least three polypeptides: the o~ chain of 55 kD (also named 
Tac or CD25, Ka  =  10 -s M); the ~ chain of 70-75 kD (Ka 
=  10 -9 M);  and a 7  chain of 56 k_D which does not bind 
IL-2 (8, 9). IL-2 was found to upregulate its own receptor 
(10, 11), whereas IL-4 was described to increase the p55 com- 
ponent (12, 13), though it inhibited the expression of high 
affinity  receptors (14, 15). 
B chronic lymphocytic leukemias (B-CLL) t are commonly 
1 Abbreviation used in this paper: B-CLL, B chronic lymphocytic leukemia. 
A. C. Fluckiger and E Garrone have contributed equally to these studies. 
defined as the accumulation in blood of slow-dividing and 
long-lived B lymphocytes dosdy resembling small resting 
B lymphocytes (16). Although B-CLL cells were first con- 
sidered to be frozen at an early stage of maturation, it was 
demonstrated subsequently that they could differentiate into 
Ig-secreting cells after activation with phorbol esters (17). 
Half of the cases express the CD25 molecule and spontane- 
ously react to IL-2 (18, 19). As with normal B cells, IL-2 
also enhances proliferation of B-CLL cells after  triggering 
through their antigen receptor (20) and through their CD40 
antigen to a lesser extent (21). B-CLL cells differentiate into 
Ig-secreting cells upon stimulation by IL-2 and PMA (22, 
23) or by IL-2 and SAC (21). 
In the present study, we demonstrate that IL-10 acts as 
a growth and differentiation factor for anti-CD40 activated 
B-CLL cells. Furthermore it is shown that IL-10 and IL-2 
act in synergy to induce the growth and differentiation of 
anti-CD40 activated B lymphocytes of both normal and leu- 
kemic origin. 
Materials and Methods 
Antibodies.  The monoclonal and polyclonal  antibodies  used for 
the phenotyping of the leukemic  B call preparations  were purchased 
from the following sources: Becton Dickinson Monodonal Center 
(Mountain View, CA): FITC-conjugated anti-CD5 (Leu 1), anti- 
CD19 (Leu 12), anti-CD20 (Leu 16), anti-CD14 (Leu M3), anti- 
CD10 (Calla), anti-HLA DR., and anti-CD25 (IL-2R) mAbs; Im- 
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and anti-CD2 (IOTll) mAbs; Dako (Glostrup, Denmark): FITC- 
conjugated F(ab)'2 fragments of rabbit anti-human IgM, IgD, IgA, 
and IgG  antibodies; Kallestad (Austin, TX):  FITC-conjugated 
F(ab)'2 fragments of donkey anti-human X or Jc light chains anti- 
bodies. The anti-CD40 mAb 89 was produced in the laboratory 
as described previously  (24). The mAbs used for the negative selec- 
tion of B cells with magnetic beads were purchased from the fol- 
lowing manufacturers:  Aster Laboratories  (La Gaude, France): anti- 
CD2 and anti-CD3 mAbs; Immunotech: anti-CD14 mAb. 
Flow Cytometric Analysis.  Cell staining was performed as de- 
scribed previously (25). Briefly, 10  s cells were incubated 15 rain 
at 4~  with the appropriate dilution of antibody in PBS-BSA-azide. 
Samples were then washed twice in the same buffer before analysis 
on a FACScan  |  (Becton Dickinson, Sunnyvale, CA). Propidium 
iodide (2/~g/ml) was added in each sample before flow cytometry 
analysis in order to gate-out nonviable cells. The negative control 
was performed  with an isotype-matched  unrelated  mAb. The pheno- 
type of proliferating cells was determined by double fluorescence 
analysis. Briefly, 106 cells were incubated during 45 min at 37~ 
with 10/~M of  Bisbenzimide Hoechst 33342 fluorochrome  (Behring 
Diagnostics, La Jolla, CA). Direct immunofluorescence staining 
was then performed using anti-CD5, anti-g and anti-X antibodies. 
Samples were analyzed with a FACStar Plus  |  (Becton Dickinson) 
equipped with a dual laser. 
Factors.  Purified  recombinant Ib2 (3  x  106 U/rag; Amgen Bi- 
ologicals, Thousand Oaks, CA) and highly purified recombinant 
human Ibl0 from CHO transfected cells (Schering-Plough Re- 
search Institute, Kenilworth, NJ) were routinely used at the final 
concentration of 20 U/ml (6.7 ng/ml) and 100 ng/ml, respectively. 
Source and Purification of  B Lymphocytes.  Normal B lymphocytes 
were isolated from tonsils. Mononuclear cells were separated by 
standard Ficoll-Hypaque  gradient method and were next submitted 
to E-rosetting with SKBC. Nonrosetting cells (E-fraction) were 
labeled with anti-T  cell (anti-CD2 and anti-CD3) and anti-monocyte 
(anti-CD14) mAbs and subsequently  incubated  with magnetic  beads 
coated with anti-mouse IgG antibodies (Dynal, Oslo, Norway). 
Residual non B cells were removed by applying a magnetic field 
for 10 min. B cell populations expressed I>99% CD19 +, CD20 +  . 
Leukemic B cells were isolated from seven patients showing the 
clinical and  immunophenotype  criteria for  B-CLL  and  were 
processed as described for the normal B cells. All pathological 
samples displayed the typical phenotype of B-CLL cells: CD5 +, 
CD19 §  , CD20 +  , CD40 +, HLA class II +, CD10-, with low in- 
tensity surface IgM coexpressed or not with IgD. Monoclonality 
can be demonstrated on the basis of  monotypic L chain expression. 
Two patients were classified as early clinical stages (Binet's stage 
A, Rai's stage I and II) and five  patients were classified  as advanced 
clinical stages (Binet's stage B and C, Rai's stage III and IV) (26, 
27). Patient FLA was treated by chemotherapy at the time of the 
study. All other patients had not received any chemotherapy in the 
3 mo preceding this study. Six samples were obtained from periph- 
eral blood and one (PAS) was obtained from spleen. 
B Cell Cultures.  Purified  leukemic and normal B cells were cul- 
tured in Iscove's medium (Flow Laboratories,  Irvine, CA) enriched 
with 50/xg/ml human transferrin (Sigma Chemical Co., St. Louis, 
MO),  0.5%  BSA, 5 /~g/ml bovine insulin, 5%  selected heat- 
inactivated FCS (all from Sigma Chemical Co.), 100 U/ml peni- 
cillin and 100/~g/ml streptomycin (both from Flow Laboratories, 
McLean, VA). For activation through the CD40 antigen, B ceils 
were cultured in the presence of the anti-CD40 mAb 89 presented 
by a mouse Ltk- cell line stably expressing CDw32  (CDw32 L 
cells) according to the experimental  procedure described previously 
(28). Briefly, 2  x  10  4 tonsillar B cells or 10  s B-CLL cells were cul- 
tured in round-bottomed microtiter trays under a final volume of 
100/~1, together with 5  x  103 irradiated (7,000 tad) CDw32 L 
cells and with the anti-CD40 mAb (0.5/~g/ml).  Cytokines were 
added at the onset of the culture. DNA synthesis was determined 
by pulsing cells with tritiated thymidine ([3H]TdR) for the final 
16 h of the culture period. Each culture point was performed in 
triplicate. Results are expressed as the mean  _+  1 SD. 
To evaluate differentiation of B cells into Ig-secreting cells, 2 
￿  104 tonsillar B cells or 10  s B-CLL cells were cultured for 12 
d in round-bottomed microtiter plates under a final volume of 200 
/~1 in the enriched medium described above. Ig levels were mea- 
sured in culture supernatants by standard ELISA  techniques as de- 
scribed elsewhere (6). Each culture point was performed in tripli- 
cate. Results are expressed as mean  _+  1 SD. 
lzsI-IL-2 Binding Assay.  Equilibrium binding of 12sI-IL-2 was 
carried out as described elsewhere (29). Cell aliquots (2-5  x  106) 
were incubated for 3 h at 4~  in the presence of various concentra- 
tions of mI-IL-2 (New England Nuclear, Boston, MA) in 250/~1 
of RPMI 1640 medium supplemented with 2% BSA and 20 nM 
Hepes, pH 7.2 (binding medium). Free 1~I-IL-2 was separated 
from surface-bound l~sI-IL-2 by rapid centrifugation on binding 
oil  (dibutyl  phtalate  [Sigma Chemical  Co.]-di[2-ethylhexyl] 
phtalate [Prolabo, Paris, France] 1-1). Nonspecific  binding was de- 
termined in the presence of 100-fold excess of cold IL-2 (Amgen 
Biologicals). 
Results 
IL-IO Enhances the DNA Synthesis of Anti-CD40 Activated 
B-CLL Cells and Synergizes with IL-2.  As IL-4 was recently 
found able to enhance the proliferation of anti-CD40 acti- 
vated B-CLL cells (21), we wondered whether IL-10 would 
also act on these cells as it does on normal B cells (3). Thus, 
10  s highly purified B-CLL ceils from seven different patients 
were cultured together with 5  x  103 irradiated CDw32 L 
cells and 0.5 #g/m1 of anti-CD40 mAb 89, with or without 
cytokines. DNA synthesis was determined as measured by 
[3H]TdR. incorporation after 7 d  of culture. As shown in 
Table 1, IL-10 enhanced by two- to fivefold the anti-CD40-in- 
duced DNA synthesis in six of seven samples. The inhibition 
by IL-10 of the anti-CD40-induced DNA synthesis of sample 
PAS was reprodudble.  The concentrations of IL-10 stimulafmg 
the DNA synthesis of anti-CD40 activated B-CLL calls were 
comparable with those inducing proliferation of anti-CD40 
activated normal B cells with a peak response being obtained 
for 30-100 ng/ml of IL-10 (data not shown). The DNA syn- 
thesis of anti-CD40 activated B-CLL cells was significantly 
stimulated with IL-2 (p =  0.02). Interestingly, combinations 
of IL-10 and IL-2 synergized to induce strong DNA syn- 
thesis  of all tested B-CLL samples  (Table 1).  This synergy 
was dose dependent, increasing with the concentrations of 
IL-10  or IL-2 (data  not shown). 
The cooperation between IL-IO and IL-2 was further ana- 
lyzed in cell  cycle studies  using DNA  labeling with the 
Hoechst 33342 fluorochrome and cell surface staining with 
FITC-conjugated anti-CD5. Fig. 1 illustrates one experiment 
performed with B cells from patient PIG. Only 0.3% of cells 
entered into S/G2/M phases  when activated in the CD40 
system. Addition of IL-2 or IL-IO to cultures increased  the 
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[3H]TdR  uptake  (cpm  x  10 -3) 
B-CLL  Medium  anti-CD40  anti-CD40  +  IL-10  anti-CD40  +  IL-2  anti-CD40  +  IL-10  +  IL-2 
BAE  0.8  1.0  2.5  1.6  14.6 
GER  0.9  2.8  6.4  5.2  25.0 
FLA  0.4  6.3  27.0  28.1  110.4 
LES  0.7  1.6  3.8  2.3  8.5 
MAG  0.2  4.1  21.4  6.7  42.9 
PIG  0.1  2.3  5.9  20.2  88.8 
PAS  0.7  6.3  3.5  13.8  31.7 
10  s B-CLL cells were cultured in the absence or in the presence of 0.5 #g/ml of anti-CD40 mAb 89 and 5,000 irradiated  CDw32 L cells (referred 
as CD40 system  or ~CD40)  without or with 100 ng/ml of IL-10,  20 U/ml of IL-2,  or a combination of IL-10  and  IL-2.  Results are expressed 
as the mean of triplicate  determination.  [3H]TdR uptake was  measured  at day 7.  SD never exceeded  10%  of the mean value. 
percentage of cells in S/G2/M to 1-2%. More strikingly,  in 
response to the combination of IL-2 and IL-10, as many as 
10.9% of the B-CLL cells were found to be in S/G2/M. All 
cells in cycle expressed either CD5 (Fig. 1) or a single L chain 
(data not shown). 
IL-IO Cooperates with IL-2  for the Proliferation of  Anti-CD40 
Activated Normal and Leukemic B Cells.  In view of the above 
findings, we tested whether IL-10 and IL-2 would cooperate 
to induce the proliferation  of normal B cells cultured in the 
CD40 system. Thus,  2  x  104 B cells were cultured over 5 
x  103 irradiated  CDw32 L cells with 0.5/~g/ml  of mAb 
89 and  [3H]TdR uptake was measured  after 5 d of incuba- 
tion.  As previously described, IL-10 elicited [3H]TdtL uptake 
of anti-CD40 activated B cells (Fig. 2 A) whereas IL-2 was 
virtually inactive whatever its concentration,  from 0.06 to 
50 U/ml (Fig. 2, A and C). Combination of IL-2 and IL-IO 
resulted  in  a strong enhancement  of the DNA synthesis. 
As illustrated  on Fig. 2, B and C, the cooperation between 
IL-2 and IL-10 was dose dependent, varying with the con- 
centrations  of IL-10 and IL-2.  100 ng/ml of IL-10 gave the 
- IL-IO  +  IL-IO 
97.7  0.3 
020  ''+:.+.  oo 
N  +~  ~,~a  +,+++,  8+e  1+'+m 
96.4 
2.4 
1.2 
￿9  ......~ :.'/,  ;'....~  :~:-" 
-2'~g,. 
/.~+!'  o.o 
i., ;~,. ~  ,.;d 
t 
96.7 
eq 
§ 
￿9  h 
o  12.0  :..,~ 
DNA  content 
1.1 
" +""  " "  0.21 
87.2  10.9 
.  ￿9  + 
1.8  i  0.1 
"~d"  ~"~/"id 
Figure  1.  Ib2 and Ibl0 synergize  to induce anti-CD40 
activated B-CLL cells to enter into cycle. 5  x  10  s B-CLL 
cells from patient PIG were cultured together with 5  x  10  + 
irradiated  CDw32 L cells and 0.5/~g/ml of mAb 89 with 
or without ID2 (20 U/m1),  IL-10 (100 ng/ml), or Ib2 and 
I1+-10. At day 7,  cells were incubated  with Hoechst 33342 
before cell surface staining with anti-CD5 mAb. Samples were 
analyzed with dual hser FACStar  ~ Numbers indicate the per- 
centage of positive cells in each quadrant.  (y-axis) CD5 ex- 
pression;  (x-axis) DNA content. 
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Figure  2.  IL-10  and IL-2 synergize for the proliferation  of anti-CD40 
activated tonsillar  B cells. 2  x  104 highly purified B cells were cultured 
together with 5,000  irradiated  CDw32 L cells and 0.5  #g/m1 of mAb 
89. (A) 20 U/m1 of IL-2, or 100 ng/ml of IL-10 or a combination of Ib2 
and Ibl0 were added.  (/3) Serial dilutions  of IIA0 were added without 
(O) or with (Q) II.-2 (20 U/ml). (C) Serial dilutions  of Ib2 were added 
without (O) or with (O) ILl0 (100 ng/ml). [3H]TdR uptake  was mea- 
sured at day 5. Results are expressed as mean  _+ SD of triplicates. Repre- 
sentative of at least three experiments. B and C were obtained with a diff~ent 
B cell sample than A, explaining  the variation  of [3H]TdR  uptake. 
maximal  growth-promoting effect with 20 U/ml of IL-2. 
Furthermore,  the  dose-response  curves illustrating  the 
[3H]TdR uptake in B cells cultured with IL-2 and serial di- 
lutions of IL-10 show a greater slope than the curve illus- 
trating the [3H]TdR uptake in B cells cultured without IL-2 
Figure  3.  Anti-CD40  activated  normal  and  leukemic  B  cells show 
different growth kinetics  in response to II.-10 and Ib2. 2  x  104 normal 
B cells (A) or 10  s B-CLL (/3) were cultured in the presence of 5,000 ir- 
radiated CDw32 L cells and 0.5 #g/ml of mAb89 (D). 100 ng/ml of Ibl0 
(O), 20 U/ml of IL-2 (m), or Ib2 and IL-10 (0) were added at the onset 
of the culture.  [3H]TdR uptake  was measured daily by 16-h pulses from 
days 2 to 9. Results are expressed as mean  _+ SD of triplicates. Two other 
experiments  performed  with distinct samples yielded  similar results. 
(Fig. 2 B).  This indicates a real synergy between IL-10 and 
IL-2. 
Kinetic studies showed that the peak response of the DNA 
synthesis induced by the combination of IL-2 and IL-10 was 
delayed on normal B cells (Fig. 3 A) when compared with 
B-CLL cells (Fig. 3 B).  For normal B cells, the peak DNA 
synthesis induced by IL-2 and IL-10 was reached at day 8, 
whereas with B-CLL cells (Fig. 3 B) the DNA synthesis rap- 
idly increased to peak at day 5. The decrease of DNA syn- 
thesis was not due to an increased cell death since Trypan 
blue dye exclusion still showed a 80% cell viability at day 7. 
The cytokine-dependent  increase of [3H]TdR uptake ac- 
tually reflected cell growth as shown by the increase of viable 
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Activated B Cells 
Viable cell recovery  (x  10 -s) 
B  cells  No  CK  IL-2  IL-10  IL-2  +  IL-10 
Tonsil  day 5  0.5  0.7  3.8  4.6 
day 7  1.7  1.9  4.1  6.6 
CLL day 5  2.1  2.6  2.5  3.5 
day 10  1.3  2.4  1.9  5.3 
103  normal  tonsillar  B  cells  or  2  x  10  s  B-CLL cells were cultured 
together with 5,000  irradiated  CDw32 L cells and 0.5/~g/ml of anti- 
CD40 mAb 89,  without or with IL-2 (20 U/m1), IL-10 (100 ng/ml), 
or a combination of IL-2 and IL-10. Viable cell recovery was determined 
by Trypan blue dye exdusion at days 5 and  7 for normal B cells and 
at days 5 and  10 for B-CLL calls. Representative of four experiments. 
cell recovery (Table 2). Addition of IL-10 increased the recovery 
of viable normal B cells cultured for 5 d in the CD40 system 
whereas IL-2 was inefficient.  Then,  the IL-10 induced cel- 
lular replication sloped. At day 7, the combination of IL-2 
and IL-10 was the most efficient, resulting in a sixfold in- 
crease of input-viable B cells. In contrast with normal B cells, 
at day 5, the number of viable anti-CD40 activated B-CLL 
cells was not increased by addition of IL-10 alone. However, 
the combination of IL-2 and IL-IO led to a fourfold increase 
of B-CLL cell counts after 10 d of culture in the CD40 system. 
11..-I0 with or without 11..-2 Elicits Differentiation of  Anti-CD40 
Activated B-CLL Cells.  We next investigated whether anti- 
CD40 activated B-CLL cells were able to differentiate in re- 
sponse to IL-IO and/or IL-2. As previously reported (21), the 
CD40 system alone ~  =  1) or with IL-2 (p  =  0.3) did not 
induce B-CLL cells  to  secrete significant  amounts  of IgM 
(Table 3). IL-IO induced five of six B-CLL samples to secrete 
fairly high levels of IgM (3.3-14.8/~g/ml) and this secretion 
was further enhanced by addition of IL-2. Actually the com- 
bination of IL-2 and IL-IO permitted the differentiation of 
the GER sample which was nonreactive  to either  IL-2 or 
Table  3.  IL-IO and 11..-2 SImergize to Induce Anti-CIMO Activated 
B-CLL Cells to Produce IgM 
IgM production 
CLL  No cytokine  IL-2  IL-10  IL-2  +  IL-10 
/~g/ml 
FLA  0.1  1.2  4.3  50 
GER  0.03  0.2  0.1  1.1 
LES  0.2  0.4  9.1  19.9 
MAG  0.3  0.2  6.3  13.7 
PAS  0.3  0.3  14.8  24.1 
PIG  0.4  0.5  3.3  7.1 
103 B-CLL cells were cultured  during 12 d in the CD40 system without 
or with IL-10 (100 ng/ml), IL-2 (20 U/ml), or a combination of IL-10 
and IL-2.  IgM levels were measured  by ELLS_4. Results are expressed 
as mean of quadruplicate  determination. SD never exceeded 10% of the 
mean value. 
IL-10. Finally, PAS secreted large amounts oflgM (14.8/~g/ml) 
in response to IL-10 in the CD40 system whereas its DNA 
synthesis measured at day 7 was inhibited by IL-10 (Table 1). 
As shown in Fig. 4, normal B lymphocytes cultured for 
12 d in the CD40 system alone or with IL-2, did not pro- 
duce a significant amount of Ig. In contrast, upon culturing 
with IL-10, B lymphocytes secreted large amounts of IgM, 
IgG, and IgA. Addition of IL-2 further stimulated IL-10-in- 
duced Ig production.  The most striking enhancement  was 
that of IgA, production of which was increased 15-fold whereas 
that of IgM and IgG was enhanced six- and threefold, respec- 
tively (means of three distinct  experiments). 
IL-IO Upregulates CD25 Expression on Normal and Leukemic 
B Lymphoqtes.  To further document the mechanism of the 
synergy between IL-10 and IL-2, we studied the influence 
of IL-10 on the expression of the IL-2 receptor on anti-CD40 
activated B cells. For this purpose, the expression of CD25/Tac 
was first analyzed by flow cytometry at different times of 
the culture period. Under all experimental conditions the pres- 
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Figure  4.  IL-10  and IL-2 syner- 
gize for the Ig production of anti- 
CD40 activated  normal B cells. 2 
x  104 highly purified  tonsfllar  B 
cells were cultured together with 5 
x  103  irradiated  CDw32 L  cells 
and 0.5/tg/ml ofmAb 89 without 
or with IL-2, IL-10, or a combina- 
tion of II..2 and IL-10. Supernatants 
were harvested at day 12 and IgM, 
IgG, and IgA levels  were  determined 
by  ELISA.  Results,  expressed  in 
#g/ml,  are  the  means  _+  SD  of 
triplicates.  No  lgE  was  ever  de- 
tected. 
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Figure 5.  IL-10  upreguhtes CD25 
expression of anti-CD40 activated 
normal or leukemic B cells. Normal 
(-.4) and CLL (B) B cells were cul- 
tured  together  with  irradiated 
CDw32  L  ceUs and  mAb  89 
without or with 1I-2 or Ibl0 or Ib2 
plus  Ibl0.  After 3  d,  cells were 
washed  twice and  stained with a 
FITC-labeled anti-CD25 or a FITC- 
labded nonrehted Ab. Fluorescence 
was  analyzed  with  a  FACScan  | 
using the same settings  as for the 
freshly isolated B cells. Histograms 
show fluorescence intensity of the 
CD25 staining (solid lines) superim- 
posed with that of the negative con- 
trol (dashed lines). 
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Figure  6.  Ibl0 enhances  the expression  of high 
af~nity IL-2 receptors on anti-CD40 activated normal 
and leukemic B cells. Two different samples of both 
normal and leukeraic B lymphocytes were cultured to- 
gether with irradiated  CDw32 L cells and mAb 89 
without or with IL-10. After 48 h, cells were washed 
twice before performing the 12Sl-IL-2 binding assays 
described in Materials and Methods.  Large panels il- 
lustrate  the equilibrium binding  data  for  t2sI-IL-2 
binding and insets represent the Scatchard analysis of 
the specific  binding data. (.4) Leukemic B cells, samples 
LES and FLA; (B) normal B cells. 
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anti-CD3 mAb. The histograms of Fig. 5 show the expres- 
sion of CD25 on anti-CD40 activated B cells in response to 
IL-2, IL-10, or combination of IL-2 and IL-IO. As previously 
described, CD25 expression was undetectable on freshly iso- 
lated tonsillar B cells (Fig. 5 A). Anti-CD40 activation slightly 
increased the expression of CD25/Tac on B cells measured 
after 3 d. In the presence of IL-10 but not IL-2, a distinct 
population  of CD25  b~sht cells emerged. Combination of 
IL-2 and IL-10 induced CD25 expression as did IL-10 alone. 
This pattern of response was observed at various times of 
culture,  45% of cells being CD25b~ig  ht between days 3 and 
4. In contrast to normal B lymphocytes, freshly isolated  B-CLL 
cells expressed low levels of CD25 which were slightly up- 
regulated by IL-IO alone in the seven tested cases (data not 
shown). After culture in the CD40 system, B-CLL cells ex- 
pressed higher levels of CD25.  IL-10 strongly upregulated 
CD25 expression on anti-CD40 activated B-CLL cells (Fig. 
5 B) whereas IL-2 was much less efficient. Combination of 
IL-2 and IL-IO resulted in an induction of CD25 which was 
higher than that obtained with IL-IO alone. The kinetic of 
CD25 upregulation was comparable with that obtained with 
normal B cells. The IL-10-induced CD25 upregulation was 
dose dependent, with the half maximal effect obtained around 
2 ng/ml and the plateau reached with "-10 ng/ml (data not 
shown). 
IL-IO Increases the Expression of  High A.~nity IL-2 Receptors 
on Anti-CiMO Activated B Cells.  The expression of IL-2 re- 
ceptors was analyzed by measuring the binding of nsI-IL-2 
on anti-CD40 activated normal and leukemic B cells, costimu- 
lated or not with IL-10. Fig. 6 shows typical binding experi- 
ments performed with two samples of normal and two samples 
of leukemic B cells and Scatchard plots of the binding data. 
B-CLL cells cultured in the CD40 system for 3 d expressed 
296 and 229 receptors per cell with a Ka of 38 and 30 pM, 
respectively, (Fig. 6 A). In the presence of IL-10, the number 
of binding sites increased to 960 and 942 receptors per cell 
with a Kd of 8 and 15 pM, respectively. On normal B cells 
(Fig. 6 B), high affinity IL-2 receptors were undetectable after 
culture in the CD40 system. When IL-IO was added to cul- 
ture,  anti-CD40 activated normal B cells showed 496 and 
582 IL-2 receptors per cell with a Kd of 40 and 46 pM. 
Discussion 
The present study demonstrates  that IL-10 enhances the 
DNA synthesis  and Ig secretion  of anti-CD40 activated  chronic 
lymphocytic leukemia B cells. The proliferating  cells were 
derived from the leukemic cell clone rather than from con- 
taminating normal B lymphocytes since  the proliferating calls 
expressed a single L chain and CD5 antigen, which is not 
upregulated on normal B cells cultured in the CD40 system 
(data not shown). In contrast with the long-lasting effect 
of IL-4 on B cell proliferation (21, 28), the growth activity 
of IL-10 was short-term and did not result in an increase of 
viable cell counts.  Indeed,  this limited growth potential of 
IL-10 on leukemic cells was also observed on normal B ceils 
(Rousset, F., and J. Banchereau, manuscript in preparation) 
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and is best explained by the IL-10-induced differentiation of 
B lymphocytes into plasma cells with a relatively short life. 
The present study also indicates that IL-10 acts as a potent 
inducer of IgM production by anti-CD40 activated B-CLL 
cells. Furthermore, numerous plasma cells were observed on 
Giemsa-stained smears (data not shown). This confirms the 
great efficiency  of IL-10 as a B cell differentiating factor and 
further extends the previous studies which demonstrated that 
B-CLL cells could differentiate into Ig-secreting cells (17, 22). 
Most importantly, upon CD40 triggering, IL-10 was found 
to synergize with IL-2 for proliferation  and differentiation 
of normal and leukemic B cells. The combination of IL-10 
and IL-2 has been, in our hands, the most efficient cytokine 
combination allowing differentiation of normal and leukemic 
B cells into Ig-secreting cells. This contrasts with the combi- 
nation of IL-10 and IL-4 which leads to an increased cellular 
replication but results in a lower Ig production (3). 
The synergy between IL-2 and IL-IO was explained by the 
property of IL-IO to upregulate the IL-2 receptors. IL-10 in- 
duced an increased expression of CD25/Tac on normal and 
leukemic B cells cultured in the CD40 system. In the ab- 
sence of cytokine, the CD40 system slightly increased the 
expression of CD25/Tac on normal B cells, but in contrast 
to anti-IgM mAb or SAC (14, 30), it did not induce high 
affinity receptors for IL-2. These results are in accordance 
with the fact that normal B cells did not proliferate in re- 
sponse to IL-2 in the CD40 system. On the other hand, B-CLL 
cells, which spontaneously  express CD25 and synthesize  DNA 
in response to IL-2, were found to express an average of 200 
high affinity IL-2 receptors with a Ko of 19 pM (data not 
shown). Accordingly, these cells incorporate [3H]TdR in re- 
sponse to IL-2 in the CD40 system. IL-IO induced high affinity 
IL-2 receptors on anti-CD40 activated normal B cells and 
increased the spontaneous  expression of high affinity IL-2 
receptors on anti-CD40 activated B-CLL cells. These data 
suggest that Ibl0 sensitizes anti-CD40 activated B lympho- 
cytes to IL-2 by inducing their high affinity IL-2 receptors. 
Very low expression of the 3 chain of the IL-2 receptor (p75) 
was detected by flow cytometric analysis on four unstimu- 
lated B-CLL populations.  After 24-48 h of incubation with 
IL-10, B chain expression significantly increased but in con- 
trast with the persistent CD25 upregulation, this phenomenon 
was transient and no more IL-2 receptor 3 chain was detected 
after 5 d of culture (our unpublished data). The surface levels 
of the IL-2 receptor ~ chain on normal B cells were unde- 
tectable by flow cytometry. 
The synergy described herein between IL-2 and IL-IO on 
anti-CD40 activated B cells was also observed, although to 
a lesser extent, on B cells activated through their antigen 
receptors. This was most conspicuous on the Ig production 
of B cells stimulated by particles of SAC (our unpublished 
results). The synergy between IL-2 and IL-10 may not be 
specific to B cells as preliminary experiments have shown that 
the two cytokines synergize for the proliferation of preacti- 
vated T cells (our unpublished results). In keeping with this, 
IL-IO was found earlier to synergize with IL-2 for the prolifer- 
ation of  mature and immature T cells (31) and their differen- 
tiation into cytotoxic effectors (32). The present results may thus explain how T cells, which 
activate  B cells in a CD40-dependent fashion (33,  34,  and 
Blanchard, D., andJ. Banchereau, manuscript in preparation) 
can induce a B cell growth and differentiation which is es- 
sentially dependent on IL-2 (35, 36). Whether IL-10 originates 
from T  cells (37,  38) or from B cells (39) during these cell 
interactions remains to be established. 
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